Showing 1–25 of 150 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Wang Y, Jing W, Liu J, Liu M
Background People living with human immunodeficiency virus (HIV) are more likely to develop tuberculosis (TB), and their co-infection (HIV-TB) increases the risk of death. We aimed to describe the global trends, regional differences and age distribution of HIV-TB. Methods Annual …
Shun-Xian Zhang, Jin-Xin Zheng, Yu Wang, Wen-Wen Lv, Jian Yang, et al.
…e years (DALYs) for TB from 1990 to 2021. Over this period, HIV-negative TB showed a marked decline in ASIR (AAPC = -2.34%, 95% CI: -2.39, -2.28) and ASMR (AAPC = -0.56%, 95% CI: -0.62, -0.59). Specifically, drug-susceptible TB (DS-TB) showed reductions in both ASIR and ASMR, whi…
Zhang SX, Wang JC, Yang J, Lv S, Duan L, et al.
…ackground The co-infection of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) and tuberculosis (TB) poses a significant clinical challenge and is a major global public health issue. This study aims to elucidate the disease burden of HIV-TB co-infecti…
Zhang J, Kern-Allely S, Yu T, Price RK
…l to provide information for resource allocation to control HIV/AIDS, tuberculosis (TB), and their co-infection, especially in areas with high morbidity and mortality like East Asia and the Pacific. Therefore, we examined the morbidity and mortality of HIV/AIDS and TB co-infectio…
Bhering M, Duarte R, Kritski A
…orldwide in the number of TB cases and 19 th in terms of TB-HIV co-infected cases. This study aims at identifying clinical and demographic factors associated with unsuccessful treatment outcomes (loss to follow-up, treatment failure and death) of HIV-positive patients with multid…
Wu Y, Zhang Y, Wang Y, Wei J, Wang W, et al.
…h drugs can achieve the greatest clinical benefit for DR-TB-HIV patients by comparing multiple chemotherapy regimens, to provide a basis for evidence-based practice. Methods We searched three electronic databases (PubMed, Web of Science and Cochrane) for related English studies p…
Tian X, Wang C, Hao Z, Chen J, Wu N
…ing trend in human immunodeficiency virus and tuberculosis (HIV-TB) in different regions from 1990 to 2021, and project future trends. Methods Global Burden of Disease Study 2021 data were analyzed to assess HIV-TB incidence, death, prevalence, and DALY rates from 1990 to 2021, i…
Ignatius EH, Swindells S
…tuberculosis (TB) incidence and mortality among people with HIV remain unacceptably high. Short-course regimens for TB, incorporating both novel and established drugs, offer the potential to enhance adherence and completion rates, thereby reducing the global TB burden. This revie…
Yuengling KA, Padayatchi N, Wolf A, Mathema B, Brown T, et al.
Background Extensively drug-resistant tuberculosis (XDR-TB)/HIV coinfection has been associated with high mortality and poor TB outcomes. We performed a prospective study to comprehensively characterize a cohort of patients with XDR-TB. Methods Adult patients with XDR-TB were enr…
Marimani M, AlOmar SY, Aldahmash B, Ahmad A, Stacey S, et al.
…ned by the high prevalence of Human Immunodeficiency Virus (HIV), the causative agent of acquired immunodeficiency syndrome (AIDS) and TB co-infections across different age groups. Epigenetic mechanisms have been widely exploited by Mtb and HIV to bypass the host's innate and ada…
Chingonzoh R, Manesen MR, Madlavu MJ, Sopiseka N, Nokwe M, et al.
…) were male, 68% (n = 982) had MDR-TB, 72% (n = 1,038) were HIV co-infected, and median age was 37 years (Interquartile Range [IQR] 30-46). Patients were at higher risk of mortality during DR-TB treatment if they were HIV co-infected not on antiretroviral treatment (ART) (adjuste…
Zhou R, Zheng T, Luo D, Zhu M, Li Q, et al.
…erculosis isolates from patients with tuberculosis (TB) and HIV, and those diagnosed with only TB in Sichuan, China. TB isolates were obtained from January 2018 to December 2020 and subjected to drug susceptibility testing (DST) to 11 anti-TB drugs and to GeneXpert MTB/RIF testin…
Zikria Saleem, Masaad Saeed Almutairi, Huda Arooj, Faris S Alnezary
…ON:** The interaction between human immunodeficiency virus (HIV) and tuberculosis (TB) presents a persistent public health challenge, particularly with the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). The Middle East and North Africa (M…
Mhango DV, Mzinza DT, Jambo KC, Mwandumba HC
Purpose of review People living with HIV (PLWH) are commonly coinfected with Mycobacterium tuberculosis, particularly in high-transmission resource-limited regions. Despite expanded access to antiretroviral therapy and tuberculosis (TB) treatment, TB remains the leading cause of …
Ntandazo Dlatu, Lindiwe M Faye, Ncomeka Sineke, Teke Apalata
…cts of body mass index (BMI), human immunodeficiency virus (HIV) status, comorbidities, socioeconomic factors, substance use and DR-TB type. **SETTING:**  The study was conducted in rural Eastern Cape, South Africa. **METHODS:**  This retrospective cohort study was de…
Omid Nikjeh, Seyedehparmis Rejali, Kayvan Sasaninia, Vishwanath Venketaraman
…ored to drug susceptibility, especially in MDR- and XDR-TB. HIV-associated mycobacterial infections-including(TB), disseminatedcomplex (MAC), and Mycobacterium()-remain leading causes of morbidity and mortality in people living with HIV (PLWH). TB continues to account for the hig…
Yuanhao Liang, Jiayi Wang, Jianzhou Yang, Jinjia Liu, Xiaofeng He
… and ASMR for all TB forms, including drug-resistant and TB-HIV co-infections. **CONCLUSION:** Sustained investment in TB control programs, particularly in low-SDI regions, is crucial. Addressing drug-resistant TB and TB-HIV co-infection should be prioritized in global public he…
Salindri AD, Kipiani M, Lomtadze N, Tukvadze N, Avaliani Z, et al.
… tuberculosis (TB) (including human immunodeficiency virus [HIV], diabetes, and hepatitis C virus [HCV]) and post-TB mortality. We conducted a retrospective cohort study among persons who initiated treatment for rifampicin-resistant or multi/extensively drug-resistant (RR or M/XD…
Peng X, Zeng Z, Hassan S, Xue Y
…B), alongside extensively drug-resistant TB (XDR-TB) and TB-HIV co-infection, TB remains one of the lead causes of death arising from infectious disease worldwide, especially in developing countries and disadvantaged populations. Marine natural products (MNPs) have received a lar…
Fang Y, Wang F, Jiang T, Duan J, Huang T, et al.
…ly infected with MPXV, human immunodeficiency virus type 1 (HIV-1), Pneumocystis jiroveci , as well as extensively drug-resistant tuberculosis (XDR-TB). This patient had also received a vaccination for smallpox in the past. Additionally, we provide photographic documentation char…
La Manna MP, Orlando V, Tamburini B, Badami GD, Dieli F, et al.
…so effective in patients with human immunodeficiency virus (HIV) coinfection. Therefore, TB control may benefit on novel therapeutic options beyond antimicrobial treatment. Host-directed immunotherapies could offer therapeutic strategies for patients with drug-resistant TB or wit…
Krasnov DV, Skluev SV, Petrova YK, Skvortsov DA, Krasnov VA, et al.
…ely drug-resistant TB, and TB-human immunodeficiency virus (HIV) coinfection require a special approach in anti-TB treatment. Most patients cannot be successfully cured by conventional chemotherapy alone. They need a modern approach using minimally invasive therapeutic and surgic…
Shetty NS, Shah I
…d preventive therapy (IPT) in human immunodeficiency virus (HIV)-infected children in India. Materials and methods Factors associated with the development of tuberculosis (TB) in 81 HIV-infected children were analyzed. Results The mean age of presentation was 6.36 ± 3.67 years. A…
Mbuh TP, Mendjime P, Goupeyou-Wandji IA, Donkeng-Donfack VF, Kahou J, et al.
…%) occurred during the first month of therapy and 13(15.5%) HIV-TB co-infected. Male gender [p = 0.006, RR = 2.5 (95% CI: 1.3-4.7)], HIV positive status [p = 0.012, RR = 2.1 (95% CI: 1.2-3.7)], and previous DR-TB status [p = 0.02, RR = 3.9 (95% CI: 1.3-12.0)] were statistically a…
Latif A, Ghafoor A, Wali A, Fatima R, Ul-Haq M, et al.
…ent among DR-TB patients with human immunodeficiency virus (HIV) co-infection (OR 11.58, 95%CI 2.20-60.72), extensively drug-resistant TB patients (OR 5.36, 95%CI 1.00-28.72), patients with exposure to both first-line and second-line anti-tuberculosis drugs (OR 2.45, 95%CI 1.21-4…